Zacks Investment Research·12h ago
Can Oscar Health Sustain Its Profit Rebound as Medical Costs Rise?Oscar Health's profit rebound faces a test as rising medical spending and a larger member base threaten second-half profitability.
Oscar Health is experiencing a dramatic growth inflection, with revenue surging 70.4% YoY to $4.9B in 2026Q2 and achieving a record combined ratio of 84.8% in 2026Q1. However, the sustainability of this profitability is questionable, as the unusually low loss ...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $1.10+173.0% vs $0.40 | $4.8B+1.3% vs $4.7B |
Q2 2026 May 6, 2026 | $2.07+71.1% vs $1.21 | $4.6B-6.4% vs $4.9B |
Q1 2026 Feb 10, 2026 | -$1.24-34.6% vs -$0.92 | $2.7B-12.1% vs $3.1B |
Q4 2025 Nov 6, 2025 | -$0.53+3.6% vs -$0.55 | $3.0B-2.2% vs $3.1B |
Oscar Health's profit rebound faces a test as rising medical spending and a larger member base threaten second-half profitability.
Oscar Health (OSCR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
OSCR, SNDR and TFII made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 23rd, 2026.
Oscar Health is upgraded to Strong Buy with a new $45 fair value, reflecting raised 2026–2029 earnings targets and an expanded TAM. Management projects 2029 EPS of $4+ and 2026 operating earnings of $600–800M, driven by ACA execution, CHOICE, and Lucie marketplace growth. CHOICE and Lucie expand OSCR's addressable market by 65%, with revenue estimates rising from $18.85B in 2026 to $32.6B in 2029.
Benchmark OSCR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Oscar Health, Inc. (OSCR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $30.53 | $7.92B | -18.07 | 27.5% | -3.79% | -44.38% | — | |
| $4.57 | $2.37B | -26.88 | 40.34% | -0.74% | -5.38% | — | |
| $7.86 | $1.62B | -2124.32 | 46.06% | 0.89% | 20.02% | — | |
| $95.16 | $33.25B | 8.19 | 14.27% | 24.44% | 19.52% | — | |
| $13.67 | $2.06B | -1.99 | — | — | -1328.94% | — | |
| $0.86 | $36.04M | -0.64 | — | — | -106.96% | — |
Oscar Health, Inc. (OSCR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Oscar Health, Inc. (OSCR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 9, 2026·SEC
Jun 8, 2026·SEC
Get notified when OSCR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Oscar Health, Inc. (OSCR) stock FAQ — growth, dividends, profitability & financials explained
Oscar Health, Inc. (OSCR) grew revenue by 27.5% over the past year. This is strong growth.
Yes, Oscar Health, Inc. (OSCR) is profitable, generating $550.7M in net income for fiscal year 2025 (-3.8% net margin).
Oscar Health, Inc. (OSCR) has a return on equity (ROE) of -44.4%. Negative ROE indicates the company is unprofitable.
Oscar Health, Inc. (OSCR) has a combined ratio of 103.4%. A ratio above 100% means claims and expenses exceed premiums.
